Vaccines broader value advisory board

11 November 2018

On the 11th of November Pfizer organized an advisory board on the broader value of vaccines. Experts of the field were invited to provide feedback on the broader benefits of vaccines and how to apply to HTA assessment to ensure full value of vaccines has been captured.

During the meeting, the different frameworks available and the usefulness of these frameworks for decision making were also discussed. Inge van der Putten was invited to give her expert opinion based on her findings on the PhD thesis: Using information on the broader economic impact of vaccines in evidence-informed decision making.